Effects of sacubitril-valsartan in patients undergoing maintenance dialysis

References

• Jankowski J, Floege J, Fliser D, et al. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1–9. doi: 10.1161/CIRCULATIONAHA.120.050686.
   Web of Science ®Google Scholar
• Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–352. doi: 10.1016/S0140-6736(13)60595-4.
   PubMed Web of Science ®Google Scholar
• Rangaswami J, McCullough PA. Heart failure in end-stage kidney disease: pathophysiology, diagnosis, and therapeutic strategies. Semin Nephrol. 2018;38(6):600–617. doi: 10.1016/j.semnephrol.2018.08.005.
   PubMed Web of Science ®Google Scholar
• Harnett JD, Foley RN, Kent GM, et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int. 1995;47(3):884–890. doi: 10.1038/ki.1995.132.
   PubMed Web of Science ®Google Scholar
• Kuhn M. Molecular physiology of natriuretic peptide signalling. Basic Res Cardiol. 2004;99(2):76–82. doi: 10.1007/s00395-004-0460-0.
   PubMed Web of Science ®Google Scholar
• Iborra-Egea O, Gálvez-Montón C, Roura S, et al. Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. NPJ Syst Biol Appl. 2017;3:12. doi: 10.1038/s41540-017-0013-4.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. doi: 10.1056/NEJMoa1409077.
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–1620. doi: 10.1056/NEJMoa1908655.
   PubMed Web of Science ®Google Scholar
• Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 2018;6(6):489–498. doi: 10.1016/j.jchf.2018.02.004.
   PubMed Web of Science ®Google Scholar
• Haynes R, Judge PK, Staplin N, et al. Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease. Circulation. 2018;138(15):1505–1514. doi: 10.1161/CIRCULATIONAHA.118.034818.
   PubMed Web of Science ®Google Scholar
• Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63(4):698–705. doi: 10.1161/HYPERTENSIONAHA.113.02002.
   PubMed Web of Science ®Google Scholar
• Cheung DG, Aizenberg D, Gorbunov V, et al. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: a randomized, double-blind, 8-week study. J Clin Hypertens. 2018;20(1):150–158. doi: 10.1111/jch.13153.
   PubMed Web of Science ®Google Scholar
• Ni X, Zhang J, Zhang P, et al. Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study. J Clin Hypertens. 2014;16(9):658–663. doi: 10.1111/jch.12374.
   Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913.
   PubMed Web of Science ®Google Scholar
• Lee S, Oh J, Kim H, et al. Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease. ESC Heart Fail. 2020;7(3):1125–1129. doi: 10.1002/ehf2.12659.
   PubMed Web of Science ®Google Scholar
• Fu S, Xu Z, Lin B, et al. Effects of Sacubitril-Valsartan in heart failure with preserved ejection fraction in patients undergoing peritoneal dialysis. Front Med. 2021;8:657067. doi: 10.3389/fmed.2021.657067.
   Web of Science ®Google Scholar
• Hsiao FC, Lin CP, Yu CC, et al. Angiotensin receptor-neprilysin inhibitors in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease: a retrospective multi-institutional study. Front Cardiovasc Med. 2022;9:794707. doi: 10.3389/fcvm.2022.794707.
   PubMed Web of Science ®Google Scholar
• Ekinci C, Karabork M, Siriopol D, et al. Effects of volume overload and current techniques for the assessment of fluid status in patients with renal disease. Blood Purif. 2018;46(1):34–47. doi: 10.1159/000487702.
   PubMed Web of Science ®Google Scholar
• Bianchi S, Aucella F, De Nicola L, et al. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian society of nephrology. J Nephrol. 2019;32(4):499–516. doi: 10.1007/s40620-019-00617-y.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Gagnor A, Calabró P, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015;385(9986):2465–2476. doi: 10.1016/S0140-6736(15)60292-6.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of america. Circulation. 2017;136(6):e137–e61. doi: 10.1161/CIR.0000000000000509.
   PubMed Web of Science ®Google Scholar
• Ortiz A, Covic A, Fliser D, et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet. 2014;383(9931):1831–1843. doi: 10.1016/S0140-6736(14)60384-6.
   PubMed Web of Science ®Google Scholar
• Karaaslan DC, Afsar B, Kanbay M. Is relative overhydration measurement by bioimpedance spectroscopy useful in reducing morbidity and mortality in chronic kidney disease? Clin Kidney J. 2018;11(3):370–371. doi: 10.1093/ckj/sfy021.
   PubMed Web of Science ®Google Scholar
• Noh H, Kim JS, Han KH, et al. Oxidative stress during peritoneal dialysis: implications in functional and structural changes in the membrane. Kidney Int. 2006;69(11):2022–2028. doi: 10.1038/sj.ki.5001506.
   PubMed Web of Science ®Google Scholar
• Fusshoeller A. Histomorphological and functional changes of the peritoneal membrane during long-term peritoneal dialysis. Pediatr Nephrol. 2008;23(1):19–25. doi: 10.1007/s00467-007-0541-z.
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhang T, Yang S, et al. Sacubitril-valsartan increases ultrafiltration in patients undergoing peritoneal dialysis: a short-term retrospective self-controlled study. Front Med. 2022;9:831541. doi: 10.3389/fmed.2022.831541.
   Web of Science ®Google Scholar
• Bayes-Genis A, Barallat J, Richards AM. A test in context: neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol. 2016;68(6):639–653. doi: 10.1016/j.jacc.2016.04.060.
   PubMed Web of Science ®Google Scholar
• Nalivaeva NN, Zhuravin IA, Turner AJ. Neprilysin expression and functions in development, ageing and disease. Mech Ageing Dev. 2020;192:111363. doi: 10.1016/j.mad.2020.111363.
   PubMed Web of Science ®Google Scholar
• Chang HY, Feng AN, Fong MC, et al. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation. J Cardiol. 2019;74(4):372–380. doi: 10.1016/j.jjcc.2019.03.010.
   PubMed Web of Science ®Google Scholar
• Raby K, Rocco M, Oparil S, et al. Heart failure primary prevention: what does SPRINT add?: recent advances in hypertension. Hypertension. 2021;77(6):1804–1814. doi: 10.1161/HYPERTENSIONAHA.121.16503.
   PubMed Web of Science ®Google Scholar
• Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure: contemporary update. JACC Heart Fail. 2017;5(8):543–551. doi: 10.1016/j.jchf.2017.04.012.
   PubMed Web of Science ®Google Scholar
• Wen Y, Xia Y, Gong Y. Effects and safety of sacubitril/valsartan (SV) on heart function and blood pressure in maintenance hemodialysis (MHD) patients. Am J Transl Res. 2022;14(5):3439–3447.
   PubMed Web of Science ®Google Scholar